A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.

A Mayer; RJ Francis; SK Sharma; B Tolner; CJ Springer; J Martin; GM Boxer; J Bell; AJ Green; JA Hartley; C Cruickshank; J Wren; KA Chester; RH Begent

doi:10.1158/1078-0432.ccr-06-0769

A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.

A Mayer, RJ Francis, SK Sharma, B Tolner, CJ Springer, J Martin, GM Boxer, J Bell, AJ Green, JA Hartley, C Cruickshank, J Wren, KA Chester, RH Begent

Cancer Research UK Manchester Institute

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	6509-6516
Number of pages	8
Journal	Clinical cancer research : an official journal of the American Association for Cancer Research
DOIs	https://doi.org/10.1158/1078-0432.ccr-06-0769
Publication status	Published - Nov 2006

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.ccr-06-0769

Cite this

Mayer, A., Francis, RJ., Sharma, SK., Tolner, B., Springer, CJ., Martin, J., Boxer, GM., Bell, J., Green, AJ., Hartley, JA., Cruickshank, C., Wren, J., Chester, KA., & Begent, RH. (2006). A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clinical cancer research : an official journal of the American Association for Cancer Research, 6509-6516. https://doi.org/10.1158/1078-0432.ccr-06-0769

Mayer, A ; Francis, RJ ; Sharma, SK et al. / A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. In: Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 ; pp. 6509-6516.

@article{de0f0149878d4f80b0f8c5fa350fc8da,

title = "A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.",

author = "A Mayer and RJ Francis and SK Sharma and B Tolner and CJ Springer and J Martin and GM Boxer and J Bell and AJ Green and JA Hartley and C Cruickshank and J Wren and KA Chester and RH Begent",

year = "2006",

month = nov,

doi = "10.1158/1078-0432.ccr-06-0769",

language = "English",

pages = "6509--6516",

journal = "Clinical cancer research : an official journal of the American Association for Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research",

}

Mayer, A, Francis, RJ, Sharma, SK, Tolner, B, Springer, CJ, Martin, J, Boxer, GM, Bell, J, Green, AJ, Hartley, JA, Cruickshank, C, Wren, J, Chester, KA & Begent, RH 2006, 'A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.', Clinical cancer research : an official journal of the American Association for Cancer Research, pp. 6509-6516. https://doi.org/10.1158/1078-0432.ccr-06-0769

A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. / Mayer, A; Francis, RJ; Sharma, SK et al.
In: Clinical cancer research : an official journal of the American Association for Cancer Research, 11.2006, p. 6509-6516.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.

AU - Mayer, A

AU - Francis, RJ

AU - Sharma, SK

AU - Tolner, B

AU - Springer, CJ

AU - Martin, J

AU - Boxer, GM

AU - Bell, J

AU - Green, AJ

AU - Hartley, JA

AU - Cruickshank, C

AU - Wren, J

AU - Chester, KA

AU - Begent, RH

PY - 2006/11

Y1 - 2006/11

UR - http://europepmc.org/abstract/med/17085666

U2 - 10.1158/1078-0432.ccr-06-0769

DO - 10.1158/1078-0432.ccr-06-0769

M3 - Article

C2 - 17085666

SN - 1078-0432

SP - 6509

EP - 6516

JO - Clinical cancer research : an official journal of the American Association for Cancer Research

JF - Clinical cancer research : an official journal of the American Association for Cancer Research

ER -

Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J et al. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Nov;6509-6516. doi: 10.1158/1078-0432.ccr-06-0769

A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Cite this